Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration

Biomaterials

Volumn 34, Issue 15, 2013, Pages 3870-3881

  Liu, Zhongyang ^a   Jiang, Mengyin ^c   Kang, Ting ^a   Miao, Deyu ^c   Gu, Guangzhi ^a   Song, Qingxiang ^b   Yao, Lei ^b   Hu, Quanyin ^a   Tu, Yifan ^a   Pang, Zhiqing ^a   Chen, Hongzhuan ^b   Jiang, Xinguo ^a   Gao, Xiaoling ^b   Chen, Jun ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Alzheimer's disease; Brain targeting; Intranasal administration; Lactoferrin; Nanoparticle; NAP

Indexed keywords

ALZHEIMER'S DISEASE; BRAIN TARGETING; INTRANASAL; LACTOFERRIN; NAP;

BRAIN; DRUG DELIVERY; DRUG DOSAGE; MOLECULAR BIOLOGY; NEURONS; PARTICLE SIZE ANALYSIS; PEPTIDES; ZETA POTENTIAL;

NANOPARTICLES;

ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; CLATHRIN; COUMARIN 6; LACTOFERRIN; LACTOFERRIN CONJUGATED POLY(ETHYLENEGLYCOL)POLY (EPSILON CAPROLACTONE) NANOPARTICLE; MALEIMIDE; NANOCARRIER; NANOPARTICLE; NEUROPROTECTIVE AGENT; PROTEIN NAP; THIOL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CAVEOLA; CEREBELLUM; CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LOW DRUG DOSE; MALE; MAZE TEST; MEMORY; NERVE CELL; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OLFACTORY BULB; OLFACTORY TRACT; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; RESPIRATORY EPITHELIUM; ZETA POTENTIAL;

ACETYLCHOLINESTERASE; ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CARBOCYANINES; CELL LINE; CHOLINE O-ACETYLTRANSFERASE; COUMARINS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; IBOTENIC ACID; LACTOFERRIN; MALE; MICE; MICE, INBRED ICR; MOLECULAR SEQUENCE DATA; NANOPARTICLES; NEUROPROTECTIVE AGENTS; PEPTIDES; POLYESTERS; POLYETHYLENE GLYCOLS; RATS, SPRAGUE-DAWLEY; THIAZOLES; TISSUE DISTRIBUTION;

MUS; RATTUS;

EID: 84874971833     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.02.003     Document Type: Article

References (73)

1. Cvetković-DoŽić D., Skender-Gazibara M., DoŽić S. Neuropathological hallmarks of Alzheimer's disease. Arch Oncol 2001, 9:195-199.
2. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
3. Smith M.A. Alzheimer disease. Int Rev Neurobiol 1998, 42:1-54.
4. Kuljis R.O., Salkovic-Petrisic M. Dementia, diabetes, Alzheimer's disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. J Alzheimers Dis 2011, 25:29-41.
5. Malerba F., Paoletti F., Capsoni S., Cattaneo A. Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin Drug Deliv 2011, 8:1277-1296.
6. Hanson L.R., Frey W.N. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008, 9(Suppl. 3):S5.
7. Thorne R.G., Emory C.R., Ala T.A., Frey W.N. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 1995, 692:278-282.
8. Illum L. Is nose-to-brain transport of drugs in man a reality?. J Pharm Pharmacol 2004, 56:3-17.
9. Danielyan L., Schafer R., von Ameln-Mayerhofer A., Bernhard F., Verleysdonk S., Buadze M., et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 2011, 14:3-16.
10. Dhuria S.V., Hanson L.R., Frey W.N. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010, 99:1654-1673.
11. Schioth H.B., Craft S., Brooks S.J., Frey W.N., Benedict C. Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol Neurobiol 2012, 46:4-10.
12. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012, 69:29-38.
13. Ali J., Ali M., Baboota S., Sahani J.K., Ramassamy C., Dao L., et al. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 2010, 16:1644-1653.
14. Verma A., Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6:12-21.
15. Ward P.P., Uribe-Luna S., Conneely O.M. Lactoferrin and host defense. Biochem Cell Biol 2002, 80:95-102.
16. Nuijens J.H., van Berkel P.H., Schanbacher F.L. Structure and biological actions of lactoferrin. J Mammary Gland Biol Neoplasia 1996, 1:285-295.
17. Hu K., Li J., Shen Y., Lu W., Gao X., Zhang Q., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 2009, 134:55-61.
18. Huang R., Ke W., Liu Y., Jiang C., Pei Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 2008, 29:238-246.
19. Elfinger M., Maucksch C., Rudolph C. Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 2007, 28:3448-3455.
20. Suzuki Y.A., Lopez V., Lonnerdal B. Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 2005, 62:2560-2575.
21. Legrand D., Pierce A., Elass E., Carpentier M., Mariller C., Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol 2008, 606:163-194.
22. Qian Z.M., Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Brain Res Rev 1998, 27:257-267.
23. Ji B., Maeda J., Higuchi M., Inoue K., Akita H., Harashima H., et al. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 2006, 78:851-855.
24. Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D.E., Spier A.D. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 2003, 20:315-322.
25. Gozes I., Steingart R.A., Spier A.D. NAP mechanisms of neuroprotection. J Mol Neurosci 2004, 24:67-72.
26. Gozes I., Morimoto B.H., Tiong J., Fox A., Sutherland K., Dangoor D., et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). Cns Drug Rev 2005, 11:353-368.
27. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999, 72:1283-1293.
28. Zemlyak I., Furman S., Brenneman D.E., Gozes I. A novel peptide prevents death in enriched neuronal cultures. Regul Pept 2000, 96:39-43.
29. Beni-Adani L., Gozes I., Cohen Y., Assaf Y., Steingart R.A., Brenneman D.E., et al. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 2001, 296:57-63.
30. Wilkemeyer M.F., Chen S.Y., Menkari C.E., Brenneman D.E., Sulik K.K., Charness M.E. Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci U S A 2003, 100:8543-8548.
31. Gozes I., Giladi E., Pinhasov A., Bardea A., Brenneman D.E. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 2000, 293:1091-1098.
32. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003, 87:187-198.
33. Gao X., Tao W., Lu W., Zhang Q., Zhang Y., Jiang X., et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 2006, 27:3482-3490.
34. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 1996, 93:14164-14169.
35. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
36. Olivier J.C., Huertas R., Lee H.J., Calon F., Pardridge W.M. Synthesis of pegylated immunonanoparticles. Pharm Res 2002, 19:1137-1143.
37. Xin H., Sha X., Jiang X., Chen L., Law K., Gu J., et al. The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles. Biomaterials 2012, 33:1673-1681.
38. Gao X., Wang T., Wu B., Chen J., Chen J., Yue Y., et al. Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles. Biochem Biophys Res Commun 2008, 377:35-40.
39. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32:8010-8020.
40. Xia H., Gao X., Gu G., Liu Z., Zeng N., Hu Q., et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011, 32:9888-9898.
41. Tran M.H., Yamada K., Nabeshima T. Amyloid beta-peptide induces cholinergic dysfunction and cognitive deficits: a minireview. Peptides 2002, 23:1271-1283.
42. Van Dam D., De Deyn P.P. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006, 5:956-970.
43. Kihara T., Shimohama S. Alzheimer's disease and acetylcholine receptors. Acta Neurobiol Exp (Wars) 2004, 64:99-105.
44. Li J., Huang H., Miezan E.J., Gao X.L., Massicot F., Dong C.Z., et al. Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. Int J Neuropsychopharmacol 2007, 10:21-29.
45. Holmes G.L., Gairsa J.L., Chevassus-Au-Louis N., Ben-Ari Y. Consequences of neonatal seizures in the rat: morphological and behavioral effects. Ann Neurol 1998, 44:845-857.
46. Pires A., Fortuna A., Alves G., Falcao A. Intranasal drug delivery: how, why and what for?. J Pharm Pharm Sci 2009, 12(3):288-311.
47. Mistry A., Stolnik S., Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009, 379:146-157.
48. Gao X., Chen J., Tao W., Zhu J., Zhang Q., Chen H., et al. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int J Pharm 2007, 340:207-215.
49. Wen Z., Yan Z., Hu K., Pang Z., Cheng X., Guo L., et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release 2011, 151:131-138.
50. Kanazawa T., Taki H., Tanaka K., Takashima Y., Okada H. Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm Res 2011, 28:2130-2139.
51. Reynoso-Camacho R., Gonzalez D.M.E., Loarca-Pina G. Purification and acute toxicity of a lectin extracted from tepary bean (Phaseolus acutifolius). Food Chem Toxicol 2003, 41:21-27.
52. Liu Q., Shao X., Chen J., Shen Y., Feng C., Gao X., et al. In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal delivery to the brain. Toxicol Appl Pharmacol 2011, 251:79-84.
53. El-Andaloussi S., Jarver P., Johansson H.J., Langel U. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J 2007, 407:285-292.
54. Kilk K., Mahlapuu R., Soomets U., Langel U. Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling. Toxicology 2009, 265:87-95.
55. Koren E., Torchilin V.P. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012, 18:385-393.
56. Li H., Sun H., Qian Z.M. The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol Sci 2002, 23:206-209.
57. Brooking J., Davis S.S., Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 2001, 9:267-279.
58. Gan C.W., Feng S.S. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010, 31:7748-7757.
59. Devalia J.L., Sapsford R.J., Wells C.W., Richman P., Davies R.J. Culture and comparison of human bronchial and nasal epithelial cells in vitro. Respir Med 1990, 84:303-312.
60. Allen C., Yu Y., Eisenberg A., Maysinger D. Cellular internalization of PCL(20)-b-PEO(44) block copolymer micelles. Biochim Biophys Acta 1999, 1421:32-38.
61. Li J., Feng L., Fan L., Zha Y., Guo L., Zhang Q., et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011, 32:4943-4950.
62. Bannerman D.M., Rawlins J.N., McHugh S.B., Deacon R.M., Yee B.K., Bast T., et al. Regional dissociations within the hippocampus-memory and anxiety. Neurosci Biobehav Rev 2004, 28:273-283.
63. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.N. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127:481-496.
64. Thorne R.G., Hanson L.R., Ross T.M., Tung D., Frey W.N. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008, 152:785-797.
65. Lochhead J.J., Thorne R.G. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012, 64:614-628.
66. Dornan W.A., Kang D.E., McCampbell A., Kang E.E. Bilateral injections of beta A(25-35) + IBO into the hippocampus disrupts acquisition of spatial learning in the rat. Neuroreport 1993, 5:165-168.
67. Morimoto K., Yoshimi K., Tonohiro T., Yamada N., Oda T., Kaneko I. Co-injection of beta-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons. Neuroscience 1998, 84:479-487.
68. Ito Y., Ito M., Takagi N., Saito H., Ishige K. Neurotoxicity induced by amyloid beta-peptide and ibotenic acid in organotypic hippocampal cultures: protection by S-allyl-L-cysteine, a garlic compound. Brain Res 2003, 985:98-107.
69. D'Hooge R., De Deyn P.P. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 2001, 36:60-90.
70. Oddo S., Caccamo A., Green K.N., Liang K., Tran L., Chen Y., et al. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A 2005, 102:3046-3051.
71. Kasa P.S., Papp H., Kasa P.J., Pakaski M., Balaspiri L. Effects of amyloid-beta on cholinergic and acetylcholinesterase-positive cells in cultured basal forebrain neurons of embryonic rat brain. Brain Res 2004, 998:73-82.
72. Boncristiano S., Calhoun M.E., Kelly P.H., Pfeifer M., Bondolfi L., Stalder M., et al. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 2002, 22:3234-3243.
73. Zemlyak I., Manley N., Sapolsky R., Gozes I. NAP protects hippocampal neurons against multiple toxins. Peptides 2007, 28:2004-2008.